AI clinical analytics platform firm Saama Technologies has made its clinical analytics platform available to integrate data from all organisations engaged in the investigation of Covid-19 treatments.
The company’s AI-powered Life Science Analytics Cloud (LSAC) technology platform will be used to set up the EndPandemic national data consortium.
The platform combines, curates, and animates clinical trial data, offering better actionable insights for rapid decision making. It will enable researchers to visualise, analyse, and interrogate data across all available programmes.
The consortium seeks to integrate data from all ongoing and future clinical studies to accelerate analysis on Covid-19 and SARS-CoV-2 research in order to decrease the time to identify a cure by up to 50%.
Saama has issued an open invitation to corporate and government organisations to mitigate the pandemic.
Saama Technologies founder and CEO Suresh Katta said: “We challenge all scientific personnel and technology companies to join the EndPandemic National Data Consortium to work together during this crisis to pool relevant data to find treatment, and hopefully a cure for SARS-CoV-2.”
The company’s LSAC platform is being used by more than 50 biotech companies on over 1,500 studies.
Earlier this month, Saama signed an agreement with Pfizer to develop and deploy an AI-powered analytics solution to reduce the challenges commonly experienced by clinical study data managers and monitors.
Saama’s LSAC platform will use deep learning techniques to aggregate, transform, analyse, model and predict clinical data queries.
Pfizer will provide the required ground truth clinical data and domain expertise to train Saama models to achieve the required accuracy.